Have a feature idea you'd love to see implemented?
Let us know!
GYRE Gyre Therapeutics Inc
Price (delayed)
$11.75
Market cap
$1.1B
P/E Ratio
51.09
Dividend/share
N/A
EPS
$0.23
Enterprise value
$1.08B
catalyst is focused on developing novel medicines to address serious medical conditions for patients who need new or better treatment options. we used a scientific approach focused on protease-based therapeutic
Highlights
Gyre Therapeutics's debt has decreased by 8% QoQ
The company's equity rose by 4.7% QoQ
GYRE's EPS has surged by 102% year-on-year but it is down by 18% since the previous quarter
GYRE's quick ratio is down by 24% year-on-year but it is up by 8% since the previous quarter
The net income has contracted by 3.8% from the previous quarter
GYRE's revenue is down by 3.3% since the previous quarter
Key stats
What are the main financial stats of GYRE
Market
Valuations
Earnings
Shares outstanding
93.52M
Market cap
$1.1B
Enterprise value
$1.08B
Price to earnings (P/E)
51.09
Price to book (P/B)
17.37
Price to sales (P/S)
5.26
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.67
Revenue
$191.34M
EBIT
-$63.35M
EBITDA
-$60.39M
Free cash flow
$26.94M
Per share
Balance sheet
Liquidity
EPS
$0.23
Free cash flow per share
$0.31
Book value per share
$0.68
Revenue per share
$2.23
TBVPS
$1.44
Total assets
$125.24M
Total liabilities
$26.77M
Debt
$1.8M
Equity
$63.18M
Working capital
$40.09M
Debt to equity
0.03
Current ratio
3.72
Quick ratio
3.45
Net debt/EBITDA
0.23
Margins
Efficiency
Dividend
EBITDA margin
-31.6%
Gross margin
96.2%
Net margin
-40.2%
Operating margin
-24.9%
Return on assets
-63.5%
Return on equity
-187.3%
Return on invested capital
-79.8%
Return on capital employed
-57.3%
Return on sales
-33.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GYRE stock price
How has the Gyre Therapeutics stock price performed over time
Intraday
-8.99%
1 week
-15.1%
1 month
-16.96%
1 year
-7.7%
YTD
-54.26%
QTD
-6.3%
Financial performance
How have Gyre Therapeutics's revenue and profit performed over time
Revenue
$191.34M
Gross profit
$183.99M
Operating income
-$47.68M
Net income
-$76.96M
Gross margin
96.2%
Net margin
-40.2%
The company's operating margin fell by 26% QoQ
GYRE's operating income is down by 22% since the previous quarter
Gyre Therapeutics's net margin has decreased by 7% QoQ
The net income has contracted by 3.8% from the previous quarter
Growth
What is Gyre Therapeutics's growth rate over time
Valuation
What is Gyre Therapeutics stock price valuation
P/E
51.09
P/B
17.37
P/S
5.26
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.67
GYRE's EPS has surged by 102% year-on-year but it is down by 18% since the previous quarter
The company's equity rose by 4.7% QoQ
The stock's price to sales (P/S) is 36% less than its last 4 quarters average of 8.2 and 35% less than its 5-year quarterly average of 8.1
GYRE's revenue is down by 3.3% since the previous quarter
Efficiency
How efficient is Gyre Therapeutics business performance
The ROE has increased by 34% since the previous quarter
GYRE's ROIC is down by 31% YoY but it is up by 21% from the previous quarter
Gyre Therapeutics's ROA has increased by 21% from the previous quarter and by 9% YoY
GYRE's return on sales is down by 13% since the previous quarter
Dividends
What is GYRE's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Dividend history
Special dividends are included in TTM DPS and yield
Financial health
How did Gyre Therapeutics financials performed over time
GYRE's current ratio is up by 29% year-on-year and by 8% since the previous quarter
GYRE's quick ratio is down by 24% year-on-year but it is up by 8% since the previous quarter
Gyre Therapeutics's debt is 97% lower than its equity
Gyre Therapeutics's debt has decreased by 8% QoQ
The company's equity rose by 4.7% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.